CSPC Pharmaceutical Group secured clinical trial clearance in China for SYS-6063, an mRNA-LNP-based dual-target CAR T-cell injection for relapsed or refractory systemic lupus erythematosus. The NMPA authorization gives the program a pathway into formal clinical development under the Chinese regulatory framework. The next step is initiation and progression of clinical evaluation of SYS-6063, as CSPC positions the platform around RNA-based engineering delivered via lipid nanoparticles—an approach intended to streamline CAR generation compared with conventional cell manufacturing workflows.